Lv1
80 积分 2025-08-13 加入
Maintenance Therapy in AML: What Is the Future Potential?
7天前
已完结
How I treat AML relapse after allogeneic HSCT
7天前
已完结
The intestinal microbiota as a key modulator of acute graft-versus-host disease
8天前
已完结
Low serum complement C3 levels are associated with adverse clinical outcomes in myelodysplastic syndromes
1个月前
已关闭
What do clinical trials teach us about the pathophysiology of human IgA nephropathy?
1个月前
已完结
Targeting the alternative complement pathway by iptacopan abrogates C3 and strongly reduces C5b-9 deposition within glomeruli in IgA nephropathy recurrence after kidney transplantation
1个月前
已完结
A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis
1个月前
已关闭
Complement Inhibition in Immunoglobulin A Nephropathy: A Mini-Review
2个月前
已完结
The expanding role of complement inhibitors in the treatment of IgA nephropathy
2个月前
已关闭
Treatment of transplantation-associated thrombotic microangiopathy with iptacopan: two cases report
2个月前
已完结
皖公网安备34019202002308
